Key statistics
On Monday, Exelixis Inc (E2XE34:SAO) closed at 104.72, 6.60% above its 52-week low of 98.24, set on Nov 03, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 107.91 |
|---|---|
| High | 107.91 |
| Low | 104.72 |
| Bid | -- |
| Offer | -- |
| Previous close | 119.13 |
| Average volume | 108.50 |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Mar 02 2026 17:41 GMT.
More ▼
Press releases
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
